News

Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent litigation over mRNA lipid nanoparticle technology, adding new international cases that raise legal and operational questions for the company’s COVID-19 vaccine business. See our latest analysis for Pfizer. The legal headlines around Pfizer’s mRNA vaccine coincide with a mixed price pattern, with the stock showing a 1-day share price return of 0.77% and a 7-day share price return of 2.85%, but a...

Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over their mRNA-LNP COVID-19 vaccines. The new cases extend beyond the existing U.S. litigation into several international jurisdictions. The lawsuits seek monetary damages and potential injunctions on vaccine products, raising legal and operational risks for Pfizer. Pfizer, listed as NYSE:PFE, is facing an expanded legal challenge as Arbutus Biopharma and Genevant Sciences...

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for […]

July 15 () - Shares of Celcuity fell about 8% in premarket trading on Wednesday, as the delayed commercial launch ‌of its newly approved breast cancer drug and treatment-tolerability ‌concerns overshadowed the company's first U. Food and Drug Administration on ​Tuesday approved gedatolisib, branded as Revtorpyk, for certain patients with advanced breast cancer whose tumors do not carry a PIK3CA mutation.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Pfizer, trading as NYSE:PFE, received FDA approval for a platinum-free Padcev-Keytruda regimen in muscle-invasive bladder cancer. The regimen is approved as both neoadjuvant and adjuvant therapy for adult patients, regardless of cisplatin eligibility. This decision expands use of the combination across a broader bladder cancer population and introduces a new treatment option. For investors watching Pfizer at a share price of $24.25, this approval adds a fresh development to the oncology...

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

Several Midtown blocks were shut down earlier this week after structural problems put the high-rise building at risk of partial collapse.

Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. This approval opens an additional use for this oncology drug. See our latest analysis for Pfizer. Despite the positive IBRANCE news and a long dividend track record, Pfizer’s recent share price performance has been weak. The stock is down over the past month and quarter, while the 1-year total...

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

(Updates with Pfizer's response in the last two paragraphs.) Pfizer (PFE) has been dismissed as a